Remedy Pharmaceuticals

Remedy Pharmaceuticals is a clinical stage pharmaceutical company that develops molecule drugs for acute central nervous system disorders.

Remedy Pharmaceuticals, Inc. develops small molecule drugs that target NCCa-ATP channels in acute central nervous system injuries, including traumatic brain injuries, strokes, and spinal cord injuries. Its RP-1127 is an intravenous version of glyburide, an inhibitor of NCCa-ATP channels that acts through antagonism of the type-1 sulfonylurea receptor. The company was founded in 2004 and is based in New York, New York.